Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1651982 | 0.81 | LMNA (0.47) | ALDH1A1L3MBTL1 | |
| SCHEMBL5763247 | 0.73 | TDP1 (0.37) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL3403141 | 0.72 | PREP (0.43) | ALDH1A1 | |
| SCHEMBL4540614 | 0.72 | CYP11B1 (0.39) | FFAR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL3411109 | 0.70 | POLB (0.44) | ALDH1A1MAPT | |
| SCHEMBL5765561 | 0.69 | CTNNB1 (0.34) | MAPT | |
| SCHEMBL5759364 | 0.69 | TDP1 (0.33) | — | |
| SCHEMBL3656546 | 0.69 | LMNA (0.41) | FFAR1ALDH1A1L3MBTL1 | |
| SCHEMBL1119080 | 0.69 | SMN1; SMN2 (0.41) | FFAR1ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL581067 | 0.69 | SMN1; SMN2 (0.55) | FFAR1ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| EP-2094682-A2 | HETEROARYL-HETEROARYL COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER, INFLAMMATION AND VIRAL INFECTIONS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008079933-A2 | HETEROARYL-HETEROARYL COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER, INFLAMMATION AND VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | FFAR1 2701/4885ALDH1A1 119/4885MAPT 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.